Kyzatrex™ effectively increases serum testosterone levels, with 87.8% of participants reaching normal levels. It alleviates symptoms like fatigue, reduced libido, and muscle loss, and improves overall well-being and psychosexual health. The drug has a stable cardiovascular profile, causing only small increases in systolic blood pressure, with minimal impact on diastolic blood pressure and heart rate. Kyzatrex™ is well tolerated, with no serious adverse events reported in clinical trials.
Further Reading:
- Dhingra, O. P., Bernstein, J., Barnes, S. D., VanLaanen, H., Wadlington, N., & Chang, J. (2021). Novel Oral Testosterone Formulation Improves Male Well Being Without Compromising International Prostate Symptom Scores. Journal of the Endocrine Society, 5(Supplement_1), A760–A760. https://doi.org/10.1210/jendso/bvab048.1546
- White, W. B., Bernstein, J. S., Rittmaster, R., & Dhingra, O. (2021). Effects of the oral testosterone undecanoate KyzatrexTM on ambulatory blood pressure in hypogonadal men. The Journal of Clinical Hypertension, 23(7), 1420–1430. https://doi.org/10.1111/jch.14297
- Bernstein, J. S., & Dhingra, O. P. (2024). A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product. Therapeutic Advances in Urology, 16. https://doi.org/10.1177/17562872241241864